Scholarlink

<p>Moyamoya disease (MMD) is a progressive cerebrovascular disorder with intracranial arterial stenosis and collateralization. Over 70% of sporadic cases lack known genetic drivers; <i>RNF213</i> variants explain only 23% of Chinese cases, highlighting unmet diagnostic and therapeutic needs. Trio-based whole-exome sequencing (WES) of 126 Chinese sporadic MMD patients (30 pediatric-parent trios) underwent cross-platform validation, cohort screening (<i>n</i> = 268), and functional analysis in human brain microvascular endothelial cells (HBMECs). Variants were prioritized by population frequency, pathogenicity, and case-control comparisons. Endothelial function and oxidative stress were assessed via proliferation, migration, tube formation, and molecular markers. WES identified 42 rare sporadic and 15 de novo mutations; Sanger validation confirmed 11 sporadic/11 de novo variants including de novo <i>NF1</i> p.Q2002X and recurrent <i>CARS1</i> p.E712V. <i>CARS1</i> p.E712V carriers showed early-onset stenosis (mean age 7.5 ± 4.4 years) and right-dominant Suzuki stage ≥4, while <i>NF1</i> p.Q2002X correlated with severe bilateral stenosis in a child (onset age 3). <i>CARS1</i> p.E712V showed significant patient enrichment (<i>P</i> = 0.004). Silencing NF1/CARS1 in HBMECs enhanced proliferation, migration, tube formation, and reduced GPX4 (CARS1-specific). <i>CARS1</i> mutation augmented angiogenesis, indicating functional alteration. This study identifies <i>NF1</i> and <i>CARS1</i> as novel susceptibility genes for sporadic MMD in Chinese, expanding the genetic landscape beyond <i>RNF213</i>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification and validation of CARS1 p.E712V and NF1 p.Q2002X in sporadic Moyamoya disease across 30 trio pedigrees

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月28日

查看全文
  • Yue Wang,
  • Zhengxing Zou,
  • Gan Chen,
  • Qian Zhang,
  • Yunzhu Li,
  • Zhengshan Zhang,
  • Xiaonan Tang,
  • Simeng Liu,
  • Tao Zhuang,
  • Dan Yu,
  • Lian Duan,
  • Wanyang Liu

摘要

Moyamoya disease (MMD) is a progressive cerebrovascular disorder with intracranial arterial stenosis and collateralization. Over 70% of sporadic cases lack known genetic drivers; RNF213 variants explain only 23% of Chinese cases, highlighting unmet diagnostic and therapeutic needs. Trio-based whole-exome sequencing (WES) of 126 Chinese sporadic MMD patients (30 pediatric-parent trios) underwent cross-platform validation, cohort screening (n = 268), and functional analysis in human brain microvascular endothelial cells (HBMECs). Variants were prioritized by population frequency, pathogenicity, and case-control comparisons. Endothelial function and oxidative stress were assessed via proliferation, migration, tube formation, and molecular markers. WES identified 42 rare sporadic and 15 de novo mutations; Sanger validation confirmed 11 sporadic/11 de novo variants including de novo NF1 p.Q2002X and recurrent CARS1 p.E712V. CARS1 p.E712V carriers showed early-onset stenosis (mean age 7.5 ± 4.4 years) and right-dominant Suzuki stage ≥4, while NF1 p.Q2002X correlated with severe bilateral stenosis in a child (onset age 3). CARS1 p.E712V showed significant patient enrichment (P = 0.004). Silencing NF1/CARS1 in HBMECs enhanced proliferation, migration, tube formation, and reduced GPX4 (CARS1-specific). CARS1 mutation augmented angiogenesis, indicating functional alteration. This study identifies NF1 and CARS1 as novel susceptibility genes for sporadic MMD in Chinese, expanding the genetic landscape beyond RNF213.